J Am Soc Nephrol 2009,
Lieberthal, Wilfred; Levine, Jerrold S
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that plays a pivotal role in mediating cell size and mass, proliferation, and survival. mTOR has also emerged as an important modulator of several forms of renal disease. mTOR is activated after acute kidney injury and contributes to renal regeneration and repair. Inhibition of mTOR with rapamycin delays recovery of renal function after acute kidney injury. Activation of mTOR within the kidney also occurs in animal models of diabetic nephropathy and other causes of progressive kidney disease. Rapamycin ameliorates several key mechanisms believed to mediate changes associated with the progressive loss of GFR in chronic kidney disease. These include glomerular hypertrophy, intrarenal inflammation, and interstitial fibrosis. mTOR also plays an important role in mediating cyst formation and enlargement in autosomal dominant polycystic kidney disease. Inhibition of mTOR by rapamycin or one of its analogues represents a potentially novel treatment for autosomal dominant polycystic kidney disease. Finally, inhibitors of mTOR improve survival in patients with metastatic renal cell carcinoma.
Diseases/Pathways annotated by Medline MESH:
Carcinoma, Renal Cell, Diabetic Nephropathies, Kidney Diseases, Kidney Diseases, Cystic, Kidney Neoplasms, Polycystic Kidney, Autosomal Dominant
Document information provided by NCBI PubMed
Text Mining Data
polycystic kidney disease — mTOR: " mTOR
an important role in mediating cyst formation and enlargement in autosomal dominant polycystic kidney disease
Manually curated Databases
No curated data.